ArticleNature medicine2019
Clonal replacement of tumor-specific T cells following PD-1 blockade.
Abstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,046 papers.
0numbers the graph read from it
0cells of the map it votes in
1,046citing papers in PubMed
71.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,046 citing papers in PubMed, 1,488 citations in OpenAlex.
- Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.Science translational medicine · 2026Trial
- Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.Nature communications · 2026Trial
- Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Trial
- Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.Nature medicine · 2026Trial
- Neoadjuvant camrelizumab combined with metronomic chemotherapy in patients with advanced esophageal squamous cell carcinoma: a pilot randomized phase 2 trial.BMC medicine · 2026Trial
- Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.Nature cancer · 2026Trial
- Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2025Trial
- 4-1BBCell reports. Medicine · 2025Trial
- Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.Nature communications · 2025Trial
- Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.Cancer discovery · 2025Trial
- The impact of gut microbiota and metabolite-driven immune cell spatiotemporal dynamics on tumors.Gut microbes · 2026Review
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Article
- Mechanisms of systemic immune modulation in tumor development: Interactions across lymph nodes, bone marrow, and blood.Cancer metastasis reviews · 2026Review
- CD39 on CD8European journal of immunology · 2026Review
- Spatial and Single-Cell Multi-Omics Analyses of T-Cell Subsets and Interactions in Melanoma Lymph Node Metastasis.Experimental dermatology · 2026Review
- Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells.Journal of translational medicine · 2026Article
- High ZFP36 Family Expression in Exhausted T Cells Is Associated With Impaired Antitumor Effector Function.Cancer science · 2026Article
- Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program.International journal of clinical oncology · 2026Article
- Article
986 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
16 authors at 5 institutions in 1 country.
Kathryn E Yost *Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA.
Ansuman T Satpathy *Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA. satpathy@stanford.edu.ORCID http://orcid.org/0000-0002-5167-537X
Daniel K WellsParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Yanyan QiCenter for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA.
Chunlin WangiRepertoire Inc, Huntsville, AL, USA.
Robin KageyamaParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Katherine L McNamaraDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Jeffrey M GranjaCenter for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA.
Kavita Y SarinDepartment of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA.ORCID http://orcid.org/0000-0001-5363-3053
Ryanne A BrownDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Rohit K GuptaStanford Biobank, Stanford University School of Medicine, Palo Alto, CA, USA.
Christina CurtisDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0166-3802
Samantha L BucktroutParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Mark M DavisParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6868-657X
Anne Lynn S ChangDepartment of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. alschang@stanford.edu.ORCID http://orcid.org/0000-0002-2869-2147
Howard Y ChangCenter for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA. howchang@stanford.edu.ORCID http://orcid.org/0000-0002-9459-4393
Stanford University · USParker Institute for Cancer Immunotherapy · USHoward Hughes Medical Institute · USiRepertoire (United States) · USStanford Medicine · US
Funding
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MTranslational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4MSpecial EquipmentP50HG007735 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2014 to 2018
$15.2MCenter for Personal Dynamic RegulomesRM1HG007735 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2019 to 2023
$13.8MLncRNA mechanisms in cancerR35CA209919 · NCI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2016 to 2022
$6.4MRepurposing systemic therapies to improve clinical outcomes in advanced basal cell cancerK23CA211793 · NCI · STANFORD UNIVERSITY · PI SARIN, KAVITA YANG · 2018 to 2022
$868kHigh Throughput DNA Sequencer UpgradeS10OD018220 · OD · STANFORD UNIVERSITY · PI COLLER, JOHN · 2014 to 2014
$596kSingle cell epigenomics in cancer immunity and immunotherapyK08CA230188 · NCI · STANFORD UNIVERSITY · PI SATPATHY, ANSUMAN · 2018 to 2020
$448kNCI NIH HHS K08 CA230188NCI NIH HHS K23 CA211793NCI NIH HHS L30 CA134161NCI NIH HHS P30 CA124435NCI NIH HHS R35 CA209919NHGRI NIH HHS P50 HG007735NHGRI NIH HHS RM1 HG007735NHLBI NIH HHS L30 HL134161NIAID NIH HHS U19 AI057229NIH HHS S10 OD018220
Abstract
Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the clinical care of patients with cancer
Indexed as
Basal Cell CarcinomaCarcinoma, Squamous CellHumansImmunotherapyLymphocytes, Tumor-InfiltratingProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellSequence Analysis, RNAT Cell Transcription Factor 1T-LymphocytesProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellT Cell Transcription Factor 1TCF7 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.